SMTI vs. LQDA, EMBC, PLSE, ESTA, FNA, EYE, BVS, AXGN, BFLY, and CBLL
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include Liquidia (LQDA), Embecta (EMBC), Pulse Biosciences (PLSE), Establishment Labs (ESTA), Paragon 28 (FNA), National Vision (EYE), Bioventus (BVS), AxoGen (AXGN), Butterfly Network (BFLY), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.
Sanara MedTech vs.
Liquidia (NASDAQ:LQDA) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership.
Liquidia has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
In the previous week, Sanara MedTech had 12 more articles in the media than Liquidia. MarketBeat recorded 14 mentions for Sanara MedTech and 2 mentions for Liquidia. Liquidia's average media sentiment score of 1.25 beat Sanara MedTech's score of 0.45 indicating that Liquidia is being referred to more favorably in the media.
Liquidia currently has a consensus target price of $25.38, suggesting a potential upside of 83.46%. Sanara MedTech has a consensus target price of $47.00, suggesting a potential upside of 24.92%. Given Liquidia's stronger consensus rating and higher possible upside, research analysts clearly believe Liquidia is more favorable than Sanara MedTech.
Sanara MedTech has higher revenue and earnings than Liquidia. Sanara MedTech is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Liquidia received 181 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 68.24% of users gave Liquidia an outperform vote while only 58.33% of users gave Sanara MedTech an outperform vote.
Sanara MedTech has a net margin of -10.71% compared to Liquidia's net margin of -765.38%. Sanara MedTech's return on equity of -19.86% beat Liquidia's return on equity.
64.5% of Liquidia shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 30.1% of Liquidia shares are held by company insiders. Comparatively, 54.1% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Liquidia beats Sanara MedTech on 10 of the 19 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sanara MedTech Competitors List
Related Companies and Tools
This page (NASDAQ:SMTI) was last updated on 1/23/2025 by MarketBeat.com Staff